Literature DB >> 29122384

Strengthening global vaccine access for adolescents and adults.

Angeline Nanni1, Stefanie Meredith2, Stephanie Gati3, Karin Holm4, Tom Harmon5, Ann Ginsberg6.   

Abstract

Global immunization efforts to date have heavily focused on infants and children, with noted success on public health. Healthy adolescents and adults contribute to the economic growth and development of countries but efforts to ensure vaccine coverage for these groups receive inadequate global attention and resources. Emerging epidemics for a number of infectious diseases including Ebola, Zika, dengue, malaria and the continuing epidemics of tuberculosis and several sexually transmitted infections, including HIV, HPV and Hepatitis B, have high incidence and prevalence in adolescents and adults. New vaccines under development for these diseases and under-used vaccines such as for human papilloma virus will have the greatest health and economic impact in these populations. Global consensus, political will, policies, global and country infrastructure, and financing mechanisms are needed to accelerate access for the billions of adolescents and adults living under the threat of devastating infectious disease outbreaks and epidemics, especially in lower income countries. The global health community and countries cannot afford to delay planning for implementation of adolescent and adult vaccine programs that will potentially save millions of lives and strengthen global and national economies. The article examines this next challenge and suggests a research agenda and a framework for action to galvanize global and national policy decision-makers to begin preparations for future immunization challenges.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adolescent and adult immunization; Ebola vaccine; Global immunization policies; HIV; HPV; Pediatric immunization; Research agenda for adolescent and adult immunization; STIs; TB; Vaccine; Vaccine delivery; Vaccine introduction; Zika

Mesh:

Substances:

Year:  2017        PMID: 29122384     DOI: 10.1016/j.vaccine.2017.10.023

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Shortening HIV vaccine regimens to achieve high coverage.

Authors:  Maria Blasi; Genevieve G Fouda
Journal:  Lancet HIV       Date:  2020-02-17       Impact factor: 12.767

Review 2.  Persistence and risk factors of high-risk human papillomavirus infection among HIV positive and HIV negative tanzanian women: a cohort study.

Authors:  Patricia Swai; Vibeke Rasch; Ditte S Linde; Bariki Mchome; Rachel Manongi; Chun Sen Wu; Marianne Waldstrom; Thomas Iftner; Julius Mwaiselage; Susanne K Kjaer
Journal:  Infect Agent Cancer       Date:  2022-06-11       Impact factor: 3.698

3.  Quantitative modeling of the effect of antigen dosage on B-cell affinity distributions in maturating germinal centers.

Authors:  Simona Cocco; Rémi Monasson; Marco Molari; Klaus Eyer; Jean Baudry
Journal:  Elife       Date:  2020-06-15       Impact factor: 8.140

4.  Health systems constraints and facilitators of human papillomavirus immunization programmes in sub-Saharan Africa: a systematic review.

Authors:  Edina Amponsah-Dacosta; Benjamin M Kagina; Jill Olivier
Journal:  Health Policy Plan       Date:  2020-07-01       Impact factor: 3.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.